Paper Details

  1. Home
  2. Paper Details

A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Giant Cell Arteritis.

Author: , BorchinRenée, CaretteSimon, CuthbertsonDavid, ForbessLindsy J, HoffmanGary S, KhalidiNader, KoeningCurry L, KrischerJeffrey P, LangfordCarol A, McAlearCarol A, McKinnonKathleen, MerkelPeter A, MonachPaul A, MorelandLarry W, PagnouxChristian, SeoPhilip, SpieraRobert, SreihAntoine G, WarringtonKenneth J, WeismanMichael, YtterbergSteven R

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Overview

Abatacept, a medication for giant cell arteritis (GCA), reduced the risk of relapse and was not associated with a higher rate of toxicity compared to prednisone alone. Patients receiving abatacept experienced a longer duration of remission than those receiving placebo.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: To compare the efficacy of abatacept to that of placebo for the treatment of giant cell arteritis (GCA). METHODS: In this multicenter trial, patients with newly diagnosed or relapsing GCA were treated with abatacept 10 mg/kg intravenously on days 1, 15, and 29 and week 8, together with p...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/28133925

データ提供：米国国立医学図書館（NLM）

The Quest for Giant Cell Arteritis Remission: A Double-Blind Trial of Abatacept

My dear friends, in the vast desert of medical research, we often encounter treacherous sandstorms of chronic inflammation. Giant Cell Arteritis (GCA), a condition that inflames the arteries, is one such tempest. This research delves into the potential of a medication called abatacept to calm this tempest and bring about remission. The researchers conducted a double-blind study, a classic method of scientific investigation, where participants were randomly assigned to receive either abatacept or a placebo. The aim was to determine if abatacept could help patients with GCA achieve a state of remission, a period where symptoms disappear or significantly lessen.

Abatacept Emerges as a Potential Ally in GCA Treatment

The results of this study, like a glistening oasis in the desert, revealed that abatacept had a positive impact on GCA. Those who received abatacept experienced a longer duration of remission compared to those who received the placebo. The study also highlighted the safety of abatacept, finding no significant difference in adverse events between the two groups.

A glimmer of hope for GCA patients

This research offers a glimmer of hope for GCA patients, suggesting that abatacept might be a valuable tool for managing the disease. However, it's important to remember that this study only involved a small number of participants. More extensive research is crucial to confirm these findings and explore the potential of abatacept in a broader context.

Dr.Camel's Conclusion

This study has provided a valuable contribution to the understanding of GCA and the potential benefits of abatacept. While further research is needed, this study offers a hopeful sign that abatacept might be able to help patients achieve a period of relief from the symptoms of GCA. Much like a camel traversing the desert, we must continue our journey to uncover new knowledge and treatments for this difficult condition.

Date :
  1. Date Completed 2017-07-18
  2. Date Revised 2022-03-11
Further Info :

Pubmed ID

28133925

DOI: Digital Object Identifier

NIHMS843037

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.